ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "morbidity and mortality"

  • Abstract Number: 724 • 2012 ACR/ARHP Annual Meeting

    Survival, Hospitalization or Need for Combination Therapy At One Year in Patients with Scleroderma-Associated Pulmonary Arterial Hypertension

    Robyn T. Domsic1, Lorinda Chung2, Jessica K. Gordon3, Yona Cloonan4, Virginia D. Steen5 and PHAROS Investigators6, 1Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, 3Rheumatology, Hospital for Special Surgery, New York, NY, 4Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, 5Department of Rheumatology, Georgetown University Medical Center, Washington, DC, 6Washington, DC, DC

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc).  Although survival has improved with PAH-specific medications in…
  • Abstract Number: 728 • 2012 ACR/ARHP Annual Meeting

    Does the Use of Angiotensin Converting Enzyme Inhibitors Prior to Scleroderma Renal Crisis Affect Prognosis ? – Results of the International Scleroderma Renal Crisis Survey

    Marie Hudson1, Murray Baron2, Solene Tatibouet1, Daniel Furst3, Dinesh Khanna4 and International Scleroderma Renal Crisis Study Investigaots5, 1Jewish General Hospital, McGill University, Montreal, QC, Canada, 2Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, 3David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, 4Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 5Montreal

    Background/Purpose: Scleroderma renal crisis (SRC) is an infrequent but life-threatening complication of systemic sclerosis (SSc). The outcome of SRC has improved considerably since the advent…
  • Abstract Number: 696 • 2012 ACR/ARHP Annual Meeting

    Risk Factors for EARLY Mortality in Scleroderma Patients: A Report From the EULAR Scleroderma Trials and Research Group (EUSTAR) Database

    Patricia E. Carreira1, Loreto Carmona2, Beatriz E. Joven3, Christopher P. Denton4, Yannick Allanore5, Ulrich A. Walker6, Marco Matucci-Cerinic7, Ulf Müller-Ladner8 and Eustar9, 1Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 2Health Sciences School, Universidad Camilo José Cela, Villanueva de la Cañada, Spain, 3Rheumatology, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, Madrid, Spain, 4Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 5Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 6Rheumatology, Universitäts-Poliklinik, Felix-Platter Spital, Basel, Switzerland, 7Department of Biomedicine & Division of Rheumatology AOUC, University of Florence, Florence, Italy, 8Abt. f. Rheumatologie u. klinische Immunologie, Osteologie, Physikalische Therapie, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, 9Florence

    Background/Purpose: to identify risk factors for early mortality in a large group of recently diagnosed systemic sclerosis (SSc) patients Methods: EUSTAR collects prospectively the Minimal…
  • Abstract Number: 697 • 2012 ACR/ARHP Annual Meeting

    Demographic, Clinical, Serologic and Socioeconomic Measures Each Predict Mortality in Scleroderma

    Allan C. Gelber1, Rebecca L. Manno2, Adrianne Woods1, Ami A. Shah3, Francesco Boin3, Laura K. Hummers3 and Fredrick M. Wigley3, 1Medicine/ Rheumatology, Johns Hopkins University, Baltimore, MD, 2Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 3Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

    Multivariate Model 1 Adjusted RR 95%CI           Multivariate Model 2 Adjusted RR 95%CI Male vs Female 1.4 1.1 – 1.9           Male vs Female 1,4…
  • Abstract Number: 698 • 2012 ACR/ARHP Annual Meeting

    External Validation of a Two-Year Mortality Risk Prediction Rule in Early Diffuse Systemic Sclerosis Patients

    Robyn T. Domsic1, Svetlana Nihtyanova2, Stephen R. Wisniewski3, Michael J. Fine4, C. Kent Kwoh5, Christopher P. Denton6 and Thomas A. Medsger Jr.7, 1Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2Department of Rheumatology, Royal Free Hospital, Medical School, London, England, 3Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 4General Medicine, University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA, 5School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 6Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 7Medicine/Rheumatology, Univ of Pittsburgh, Pittsburgh, PA

    Background/Purpose:   The ability to risk stratify patients for short term mortality is important in SSc patient care and clinical trial design; but there is…
  • Abstract Number: 290 • 2012 ACR/ARHP Annual Meeting

    Long-Term Outcomes in Neonatal Lupus

    Amit Saxena1, Peter M. Izmirly2, Deborah Friedman3 and Jill P. Buyon4, 1Medicine, New York University School of Medicine, New York, NY, 2Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 3Division of Pediatric Cardiology, New York Medical College, Valhalla, NY, 4Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: Several studies have evaluated mortality and short-term morbidity in neonatal lupus (NL), however there have been no substantive descriptions of the long term cardiac,…
  • Abstract Number: 291 • 2012 ACR/ARHP Annual Meeting

    Illness Features Associated with an Increased Risk of Mortality in Children with Juvenile Idiopathic Inflammatory Myopathies

    Adam M. Huber1, Gulnara Mamyrova2, Julia A. Lee3, Peter A. Lachenbruch4, Ira N. Targoff5, Frederick W. Miller4, Lisa G. Rider4 and Childhood Myositis Heterogeneity Study Group6, 1Dalhousie University, Halifax, NS, Canada, 2Rheumatology, George Washington University, Washington, DC, 3Environmental Autoimmunity Grp, NIEHS, Bethesda, MD, 4Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 5Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, 6Bethesda, MD

    Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are potentially life-threatening systemic autoimmune diseases but little in known regarding factors associated with mortality. Methods: Patients enrolled in…
  • Abstract Number: 217 • 2012 ACR/ARHP Annual Meeting

    Myositis-Associated Usual Interstitial Pneumonia Has Better Survival Than Idiopathic Pulmonary Fibrosis

    Christine McBurney1, Rohit Aggarwal2, Kevin Gibson3, Kathleen Lindell4, Carl Fuhrman5, Diane Koontz6, Frank Schneider7, Naftali Kaminski4 and Chester V. Oddis8, 1Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2Medicine, University of Pittsburgh, Pittsburgh, PA, 3Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4University of Pittsburgh Dorothy P. & Richard P. Simmons Center for Lung Disease, Pittsburgh, PA, 5Radiology, Division of Thoracic Imaging, University of Pittsburgh, Pittsburgh, PA, 6Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Anatomic Pathology Department, Pittsburgh, PA, 8Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Usual interstitial pneumonia associated with idiopathic pulmonary fibrosis (IPF-UIP) has a poor prognosis with a median survival of 3 years. It is unknown whether…
  • Abstract Number: 2559 • 2012 ACR/ARHP Annual Meeting

    Mortality in Patients with Psoriatic Arthritis Compared to Patients with Rheumatoid Arthritis, Psoriasis Alone, and the General Population

    Alexis Ogdie1, Kevin Haynes2, Andrea Troxel2, Thorvardur Love3, Hyon K. Choi4 and Joel Gelfand5, 1Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, 2Clinical Epidemiology and Biostatistics, University of Pennsylvania., Philadelphia, PA, 3Landspitali University Hospital, Reykjavik, Iceland, 4Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 5University of Pennsylvania., Philadelphia, PA

    Background/Purpose: Conflicting reports of the mortality risk among patients with psoriatic arthritis (PsA) exist in the literature, however excess mortality has been presumed given the…
  • Abstract Number: 2044 • 2012 ACR/ARHP Annual Meeting

    Trying to Improve Care: A Review of the Morbidity and Mortality Conference in the Division of Rheumotology

    Michelle Batthish1, Shirley Tse2, Brian M. Feldman3, G. Ross Baker4 and Ronald Laxer5, 1Pediatric Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 2Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 4Institute of Health Policy, Management and Evaluation, The University of Toronto, Toronto, ON, Canada, 5Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: The morbidity and mortality conference (M&MC) is one of academic medicine’s most visible fora for discussion of adverse events and errors; however it is…
  • Abstract Number: 1665 • 2012 ACR/ARHP Annual Meeting

    Associations of Race and Ethnicity with Overall Mortality and Cardiovascular Events Among Patients with End-Stage Renal Disease Due to Lupus Nephritis

    Jose A. Gomez-Puerta1, Sushrut Waikar2, Graciela S. Alarcon3, Jun Liu4, Daniel H. Solomon5, Wolfgang C. Winkelmayer6 and Karen H. Costenbader7, 1Section of Clinical Sciences, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, 2Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, 3Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 4Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, 5Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, 6Division of Nephrology, Stanford University School of Medicine, Stanford, CA, 7Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Patients with SLE and lupus nephritis (LN) are at elevated risks of cardiovascular disease. Past studies have suggested that African American patients with SLE…
  • Abstract Number: 1407 • 2012 ACR/ARHP Annual Meeting

    The Effect of the Antiphospholipid Syndrome (APS) On Survival in Chinese Patients with SLE: A Prospective Study of 679 Patients

    Chi Chiu Mok, Ling Yin Ho, Ka Lung Yu and Chi Hung To, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong

    Background/Purpose:  To study the effect of the antiphospholipid syndrome (APS) on survival in Chinese patients with SLE Methods: A cohort of 679 southern Chinese patients…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology